Company / Net Income
Spero Therapeutics, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$68.6M
FY2025
5-year range
-$89.8M / $22.8M
FY2021-FY2025
Trend
-400.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed -401% YoY in FY2025, a notable deviation from the 7-year average annual change of -51%.
Based on SEC 10-K filings.
-$69M in FY2025.
Declined from -$46M to -$69M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 400.6% year-over-year.
- Peak net income was recorded in FY2024.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$68.6M | -400.6% |
| FY2024 | $22.8M | +149.1% |
| FY2023 | -$46.4M | +48.3% |
| FY2022 | -$89.8M | -14.6% |
| FY2021 | -$78.3M | -28.6% |
| FY2020 | -$60.9M | -46.0% |
| FY2019 | -$41.7M | -63.6% |
| FY2018 | -$25.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026